One Lambda Pre-Transplant Risk Assessment Assay

Introducing the Pre-Transplant Risk Assessment (PTRA) Assay

This risk assessment assay is designed to assess patient risk for early acute rejection based on gene expression profiling. The assay demonstrated a negative predictive value (NPV) of 96.7%¹, and data from this test may help support a more individualized understanding of patient risk prior to transplant, in the context of balancing the risk of rejection and the adverse effects of over-immunosuppression.

The limitations of standardized immunosuppression protocol

While standardized immunosuppression protocols may reduce overall rejection rates, they often fail to account for diverse clinical and demographic profiles inherent in different transplant populations. Such approaches can result in suboptimal dosing, leading to a precarious balance between graft rejection and drug-induced toxicity. In particular, standardized regimens may lead to:

Over-immunosuppression, which may lead to poor long-term outcomes²
Patient complications such as toxicity, cancer and serious infections³
Considerable costs to the healthcare system⁴

Key features and benefits

Seamless integration: Minimally invasive blood draw which may be performed concurrently with other pre-transplant labs
Quick results: Results available in as little as 3-5 days from specimen receipt
Impact on cost of care: Adverse events in the first 60 days after transplant can cost hospitals as much as $10k per episode⁴. Tools like the Pre-Transplant Risk Assessment Assay, which enable patient risk assessment, may provide opportunities for health system savings
User-friendly analysis: Provides easy to interpret results (high risk vs low risk)

Thought leadership on immunosuppression management

Key discussion points include:

Challenges with immunosuppression management
Advantages of tools that minimize adverse effects of immunosuppression
Limitations of traditional testing

Learn more about the Pre-Transplant Risk Assessment testing service

References

Gallon L, Chang A, Kattan M, Donovan M. (2023, November 2). Multi-center international study to validate a pre-transplant blood-based NGS signature predicting risk of acute rejection after kidney transplant. 2023 American Society of Nephrology Meeting, Philadelphia, PA, United States.
Szumilas K, Wilk A, Wiśniewski P, et al. Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation. Int J Mol Sci. 2023;24(12):10301. Published 2023 Jun 18. doi:10.3390/ijms241210301.
Wojciechowski D, Wiseman A. Long-Term Immunosuppression Management: Opportunities and Uncertainties. Clin J Am Soc Nephrol. 2021;16(8):1264-1271. doi:10.2215/CJN.15040920.
Famure O, Kim ED, Au M, et al. What Are the Burden, Causes, and Costs of Early Hospital Readmissions After Kidney Transplantation?. Prog Transplant. 2021;31(2):160-167. doi:10.1177/15269248211003563.

The One Lambda Laboratories Pre-Transplant Risk Assessment (PTRA) assay is a test that was developed and validated by One Lambda Laboratories. This laboratory-developed test (LDT) is used for clinical purposes by the CLIA-certified laboratory performing the test. This test has not been cleared or approved by the FDA as an in vitro diagnostic test.

Testing protocols vary by transplant center and a patient’s level of risk. This presentation is offered for informational purposes only and does not reflect all available diagnostic procedures or treatments and is not meant to be a substitute for advice from a qualified healthcare professional.